MSN Labs unveils generic Favipiravir under brand name Favilow 800 mg at Rs 144 per tablet

Published On 2021-04-29 06:30 GMT   |   Update On 2021-04-29 11:04 GMT

New Delhi: MSN Laboratories on Wednesday said it has launched the generic version of antiviral drug Favipiravir in 800 mg strength for treating mild and moderate COVID-19 patients.The company''s drug to be sold under the brand name ''Favilow 800 mg'' is priced at Rs 144 per tablet and will be available across pharmacies, MSN Laboratories said in a statement."In the light of increasing...

Login or Register to read the full article

New Delhi: MSN Laboratories on Wednesday said it has launched the generic version of antiviral drug Favipiravir in 800 mg strength for treating mild and moderate COVID-19 patients.

The company''s drug to be sold under the brand name ''Favilow 800 mg'' is priced at Rs 144 per tablet and will be available across pharmacies, MSN Laboratories said in a statement.

"In the light of increasing COVID-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation''s efforts in overcoming the COVID crisis," MSN Group Chairman and Managing Director MSN Reddy said.

Read also: Fujifilm to restart clinical trial of Avigan for COVID-19 treatment: Report

The company had launched the drug in the strengths of 200 mg and 400 mg in August 2020, the statement said.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News